Vor Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview

Vor Biopharma

07/05/2024 13:20

* Vor Biopharma Inc  VOR.OQ   VOR.O  is expected to show no
change
in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Vor Biopharma Inc is for
a
loss of 38 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $13.50​, above​ its last closing price of $1.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.52       -0.50      -0.39     Beat    22.5
 Sep. 30 2023  -0.47       -0.47      -0.49     Missed  -4.6
 Jan. 1 0001   -0.44       -0.43      -0.45     Missed  -4.1​
 Mar. 31 2023  -0.39       -0.38      -0.43     Missed  -12.2
 ​​Dec.        -0.47       -0.60      -0.52     Beat    13.7
 31 2022                                                
 Sep. 30 2022  -0.60       -0.61      -0.63     Missed  -3.7​
 Jun. 30 2022  -0.66       -0.66      -0.58     Beat    11.9
 Mar. 31 2022  -0.52       -0.51      -0.61     Missed  -18.9
 This summary was machine generated May 7 at 12:19 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)